Nexalis Therapeutics (ASX:NX1) Other Current Payables: A$0.18 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nexalis Therapeutics Other Current Payables?

Nexalis Therapeutics ASX:NX1 +10.00% Other Current Payables is A$0.18 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Nexalis Therapeutics's Other Current Payables for the quarter that ended in Dec. 2025 was A$0.18 Mil.

Nexalis Therapeutics's quarterly Other Current Payables declined from Dec. 2024 (A$0.17 Mil) to Jun. 2025 (A$0.00 Mil) but then increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.18 Mil).

Nexalis Therapeutics's annual Other Current Payables increased from Dec. 2023 (A$0.17 Mil) to Dec. 2024 (A$0.17 Mil) and increased from Dec. 2024 (A$0.17 Mil) to Dec. 2025 (A$0.18 Mil).

Nexalis Therapeutics Other Current Payables Related Terms

Nexalis Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Nexalis Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalis Therapeutics Other Current Payables Chart

Nexalis Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.08 0.17 0.17 0.18

Nexalis Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.00 0.17 0.00 0.18

Nexalis Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of A$0.18 Mil mean?
Nexalis Therapeutics (ASX:NX1) has a Other Current Payables of A$0.18 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Nexalis Therapeutics and its competitors.
Is Nexalis Therapeutics' Other Current Payables too high?
Nexalis Therapeutics' current Other Current Payables is A$0.18 Mil.
How does Nexalis Therapeutics' Other Current Payables compare to VRTX and REGN?
Nexalis Therapeutics' Other Current Payables of A$0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current Other Current Payables is A$0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current Other Current Payables of A$0.18 Mil. The current Other Current Payables is A$0.18 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current Other Current Payables is A$0.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.